Prostate-specific antigen for prostate cancer staging in a population-based register

Scandinavian Journal of Urology and Nephrology

Volumn 36, Issue 2, 2002, Pages 99-105

  Sandblom, G ^a   Holmberg, L ^b   Damber, J E ^c   Hugosson, J ^c   Johansson, J E ^d   Lundgren, R ^e   Mattsson, E ^b   Nilsson, J ^b   Varenhorst, E ^f  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^e HELSINGBORG HOSPITAL   (Sweden)

^f Norrköping and Finspång Hospitals ^*  (Sweden)

Author keywords

Neoplasm staging; Prostate specific antigen; Prostatic neoplasms; Registries

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREVALENCE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR VOLUME;

AGED; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; SENSITIVITY AND SPECIFICITY;

EID: 0036236988     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655902753679373     Document Type: Article

References (24)

1. Prostate carcinoma trends in three counties in Sweden 1987-1996. Results from a population-based National Cancer Register
2. Role of prostate-specific antigen as a predictor of outcome in prostate cancer
3. The prognostic value of different forms of prostate-specific antigen and their ratios in patients with prostate cancer
4. Prediction of pathological stage and clinical outcome in prostate cancer: An improved pre-operative model incorporating biopsy-determined intraductal carcinoma
5. Guidelines on the management of prostate cancer
6. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of prostate cancer
7. Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer
8. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer
9. Predictive value of prostate-specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer
10. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters
11. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate
12. Prostate cancer registration in four Swedish regions 1996. Differences in incidence, age structure and management
13. Progress in standardization of immunoassays for prostate-specific antigen
14. Reference material for PSA: The IFCC standardization study
15. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients
16. Small cell and anaplastic prostate cancer: Correlation between CT findings and prostate-specific antigen level
17. Biases in the assessment of diagnostic tests
18. Incidence, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer
19. Radical retropubic prostatectomy for localized prostatic carcinoma: A clinical and pathological study of 201 cases
20. Significance of histological prognostic indicators in patients with carcinoma of the prostate
21. When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis